至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor

J Thromb Haemost. 2018; 
de Jong A, Dirven RJ, Oud JA, Tio D, van Vlijmen BJM, Eikenboom J.
Products/Services Used Details Operation
Recombinant Proteins … Samples were diluted in blocking buffer, and plates were incubated with diluted sample for 2 h. Wells were incubated with the secondary polyclonal antibody rabbit anti‐c‐Myc‐tag‐HRP (GenScript, Piscataway, NJ, USA) for 2 h. OPD conversion was performed as described … Get A Quote

摘要

Essentials Substitution therapy for von Willebrand (VW) disease leaves mutant VW factor (VWF) unhindered. Presence of mutant VWF may negatively affect phenotypes despite treatment. Inhibition of VWF by allele-specific siRNAs targeting single-nucleotide polymorphisms is effective. Allele-specific inhibition of VWF p.Cys2773Ser improves multimerization.,Background Treatment of the bleeding disorder von Willebrand disease (VWD) focuses on increasing von Willebrand factor (VWF) levels by administration of desmopressin or VWF-containing concentrates. Both therapies leave the production of mutant VWF unhindered, which may have additional consequences, such as thrombocytopenia in patients with VWD type 2B, competition... More

关键词